" /> FOLFIRI-Bevacizumab Regimen - CISMeF





Preferred Label : FOLFIRI-Bevacizumab Regimen;

NCIt synonyms : Folinic Acid-Fluorouracil-Irinotecan-Bevacizumab Regimen; FOLFIRI-Avastin Regimen; FOLFIRI/Bevacizumab Regimen;

NCIt related terms : Bevacizumab IFL; FOLFIRI and Bevacizumab (L-Leucovorin); FOLFIRI and Bevacizumab; FOLFIRI and Bevacizumab-awwb; FOLFIRI and Bevacizumab-equi (L-Leucovorin); FOLFIRI and Bevacizumab-aybi; FOLFIRI and Bevacizumab-bvzr; FOLFIRI and Bevacizumab-maly (L-Leucovorin); FOLFIRI and Bevacizumab-adcd (L-Leucovorin); FOLFIRI and Bevacizumab-equi; FOLFIRI and Bevacizumab-adcd; FOLFIRI and Bevacizumab-onbe (L-Leucovorin); FOLFIRI and Bevacizumab-aybi (L-Leucovorin); FOLFIRI and Bevacizumab-awwb (L-Leucovorin); FOLFIRI and Bevacizumab-onbe; FOLFIRI and Bevacizumab-maly; FOLFIRI and Bevacizumab-bvzr (L-Leucovorin);

NCIt definition : A regimen consisting of bevacizumab, fluorouracil, irinotecan and leucovorin that may be used in the treatment of ampullary and appendiceal adenocarcinoma, colorectal cancer, and small bowel adenocarcinoma.;

Alternative definition : NCI-GLOSS: A chemotherapy combination used as an initial treatment of colorectal cancer that has spread. It includes the drugs leucovorin (folinic acid), fluorouracil, irinotecan hydrochloride, and bevacizumab.;

NCIt note : Source: NCCN Guidelines and PDQ;

Codes from synonyms : CDR0000662508; CDR0000662509; 14656; 4391; 127542; 127323; 127246; 127545; 127468; 127249; 127320; 127616; 127619; 127172; 127394; 127471; 127175; 127397;

Details


Keyword's position in hierarchy(ies) : arborescence

You can consult :


Nous contacter.
30/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.